However, NSCLC patients on CTLA‐4 inhibitors less frequently develop checkpoint inhibitor pneumonitis (CIP) compared to those on PD‐1/PD‐L1 inhibitors, although underreporting is a concern.7, 31, 32, 33, 34, 35, 36. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.